The Oncology Institute Adds Healthcare Veteran Kim Tzoumakas to Board
Event summary
- Kim Tzoumakas appointed to The Oncology Institute’s Board of Directors on February 23, 2026.
- Tzoumakas brings over 20 years of executive leadership experience in oncology, pharmacy services, and healthcare operations.
- Former CEO of 21st Century Oncology, where she led a multi-year operational turnaround culminating in a strategic sale.
- Currently serves as CEO of VytlOne National Pharmacy Services and has board experience with multiple healthcare companies.
The big picture
The Oncology Institute’s appointment of Kim Tzoumakas reflects a strategic move to bolster its board with deep industry experience as it expands its care delivery model. Tzoumakas’ background in operational turnarounds and integrated care aligns with TOI’s focus on value-based oncology, positioning the company to navigate the evolving healthcare landscape. With over 100 clinics and affiliate locations across five states, TOI is leveraging governance enhancements to support its growth ambitions.
What we're watching
- Strategic Expansion
- How Tzoumakas’ expertise in oncology and pharmacy services will influence TOI’s growth in employed and MSO networks.
- Operational Efficiency
- Whether Tzoumakas’ track record in cost management and integrated care delivery can enhance TOI’s operational performance.
- Board Dynamics
- The impact of Tzoumakas’ addition on TOI’s governance and strategic decision-making.
Related topics